News und Analysen

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences:

• 
  The 2025 Wells Fargo Healthcare Conference on

Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, has been named a Certified™ Great Place To Work® for the fourth consecutive year and has earned a place on

Monsanto has now reached agreements in principle to resolve all Sky Valley Education Center cases, representing more than 200 plaintiffs overall, with the exception of the prior adverse verdicts

Bayer’s Aspirina, the #1 pain relief option in Mexico¹, is now available for purchase in the United States, bringing a well-known brand to the Hispanic community. With a deep commitment to Hispanic

Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss

Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2025.

Second Quarter 2025 Financial Highlights:

• 
  Revenue grew 15% year-over-year to

Regulatory News:

Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss

Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has